Please assess the completion status of the following clinical trial:

Trial Title: A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced Multiple Myeloma.~* Progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (iMID), one alkylator, and bortezomib (VELCADE®).~* ECOG performance status of either 0 or 1.~Exclusion Criteria:~* Prior chemotherapy with antimicrotubule agents~* Metastasis involving the brain or spinal cord~* Clinically significant lung or heart disease~* Abnormal electrocardiogram~Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.~Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- One (Type: EXPERIMENTAL): Noscapine HCl

Based on this trial design, predict the completion outcome and termination type (if applicable).